会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 3. 发明申请
    • MECHANISM OF NEUROMEDIN U ACTION AND USES THEREOF
    • 神经母细胞瘤的作用机制及其用途
    • US20110294735A1
    • 2011-12-01
    • US13122783
    • 2009-10-30
    • Donald J. MarshAndrea M. PeierAlessandro Pocai
    • Donald J. MarshAndrea M. PeierAlessandro Pocai
    • A61K38/16G01N30/00A61P3/04A61P3/10G01N33/74A61P3/00
    • G01N33/74A61K31/425A61K38/22A61K45/06G01N33/566G01N2333/605G01N2800/52A61K2300/00
    • The use of neuromedin U receptor agonists to elevate the levels of GLP-1 and/or PYY in an individual in need of an increase in its levels of GLP-1 and/or PYY is described. Further described is the use of neuromedin U receptor agonists to lower the levels of glucagon in an individual in need of lowered glucagon levels. Thus, methods for elevating GLP-1 and/or PYY and lowering glucagon levels in an individual by administering to the individual compositions comprising a neuromedin U receptor agonist and optionally one or more dipeptidyl peptidase IV (DPP-IV) inhibitors are described. In light of the ability of NMU receptor agonists to raise GLP-1 and PYY levels and lower glucagon levels post-administration, methods are described for evaluating the efficacy of a treatment regimen for a metabolic disorder that includes administering a composition comprising a neuromedin U receptor agonist to an individual comprising measuring the level of glucagon-like peptide 1 (GLP-1) and/or peptide YY (PYY) and/or glucagon in the individual before, during, and after the treatment regimen.
    • 描述了使用神经介肽U受体激动剂来提高需要GLP-1和/或PYY水平增加的个体中GLP-1和/或PYY的水平。 进一步描述的是使用神经介肽U受体激动剂来降低需要降低胰高血糖素水平的个体中胰高血糖素的水平。 因此,描述了通过给予包含神经介肽U受体激动剂和任选的一种或多种二肽基肽酶IV(DPP-IV)抑制剂的个体组合物来降低个体中GLP-1和/或PYY并降低胰高血糖素水平的方法。 鉴于NMU受体激动剂在给药后提高GLP-1和PYY水平和降低胰高血糖素水平的能力,描述了评估治疗方案对于代谢紊乱的功效的方法,其包括施用包含神经介肽U受体的组合物 激动剂,其包括在治疗方案之前,期间和之后测量个体中胰高血糖素样肽1(GLP-1)和/或肽YY(PYY)和/或胰高血糖素的水平。